SCHEMBL21147247

SCHEMBL21147247

Brc1ccc(-c2cc(-c3ccccc3)ccc2-n2c3ccccc3c3ccccc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
MAPK1 P28482 1/20 0.46
ATM Q13315 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
KDM4E B2RXH2 1/20 0.38
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
IDO2 Q6ZQW0 1/20 0.37
PARP1 P09874 1/20 0.36
GRM2 Q14416 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ACHE P22303 2/20 0.35
BCHE P06276 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17194711 0.93 ALDH1A1 (0.40) ALDH1A1MAPK1ATML3MBTL1KDM4E
SCHEMBL15791590 0.93 ALDH1A1 (0.40) ALDH1A1MAPK1ATML3MBTL1KDM4E
SCHEMBL25941976 0.93 MEN1 (0.38) ALDH1A1MAPK1ATML3MBTL1KDM4E
SCHEMBL21165689 0.92 L3MBTL1 (0.44) ALDH1A1ATML3MBTL1KDM4ENPC1
SCHEMBL17040746 0.92 ALDH1A1 (0.39) ALDH1A1MAPK1ATML3MBTL1KDM4E
SCHEMBL21588561 0.89 IDO1 (0.46) ALDH1A1MAPK1ATML3MBTL1KDM4E
SCHEMBL21708988 0.88 TSPO (0.43) ALDH1A1ATML3MBTL1KDM4ENPC1
SCHEMBL17056744 0.88 PARP1 (0.37) ALDH1A1MAPK1ATML3MBTL1KDM4E
SCHEMBL16947241 0.88 PARP1 (0.37) ALDH1A1MAPK1ATML3MBTL1KDM4E
SCHEMBL17194733 0.86 TSPO (0.37) ALDH1A1ATML3MBTL1KDM4EIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11706977-B2 Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-07-18 US disclosed
US-11706977-B2 Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-07-18 US disclosed
US-20190214570-A1 HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND SAMSUNG ELECTRONICS CO., LTD. (KR) 2019-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11706977-B2 Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound CRY1, CYP1B1, CYP1A1 ALDH1A1 40/4885MAPK1 1289/4885ATM 2932/4885
US-20190214570-A1 HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND CRY1, CYP1B1, CYP1A1 ALDH1A1 40/4885MAPK1 1289/4885ATM 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.